Skip to content
Evigrade
CriticalAntiretroviral, HIV protease inhibitor×HMG-CoA reductase inhibitor (statin)

Updated · Methodology

Mechanism

Lovastatin metabolism depends heavily on CYP3A4, and atazanavir, which inhibits this enzyme, can raise lovastatin levels (atazanavir summary of product characteristics, SmPC, European Medicines Agency, EMA). Atazanavir is an HIV protease inhibitor (EMA). The lovastatin SmPC lists HIV protease inhibitors among strong CYP3A4 inhibitors. They raise plasma inhibitory activity against HMG-CoA reductase, the enzyme that statins act on, and with it the risk of myopathy and rhabdomyolysis (lovastatin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Ritonavir inhibits CYP3A4 more strongly than atazanavir itself, and cobicistat is also a potent CYP3A inhibitor (atazanavir and atazanavir/cobicistat SmPCs, EMA). The documents give no figures for this pair.

Symptoms

Myopathy presents as muscle pain, tenderness or weakness with creatine kinase (CK) above 10 times the upper limit of normal (lovastatin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Myopathy sometimes progresses to rhabdomyolysis (muscle breakdown), with or without acute kidney failure due to myoglobin in the urine. Rarely, it is fatal (AEMPS). A warning sign is unexplained muscle pain, tenderness or weakness, especially with malaise or fever (lovastatin label, US Food and Drug Administration, FDA).

Management

The combination is contraindicated. Lovastatin is named in the contraindications of atazanavir regardless of the booster: in the European and US atazanavir documents and in the atazanavir/cobicistat SmPC (atazanavir and atazanavir/cobicistat summaries of product characteristics, SmPCs, European Medicines Agency, EMA; atazanavir label, US Food and Drug Administration, FDA). With ritonavir, the ritonavir SmPC also contraindicates lovastatin (ritonavir SmPC, EMA). The lovastatin documents also list HIV protease inhibitors among the contraindicated strong CYP3A4 inhibitors (lovastatin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; lovastatin FDA label). The Spanish lovastatin SmPC provides for pausing lovastatin during an unavoidable course of itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin only. HIV protease inhibitors are not on this list (AEMPS). For other statins, the atazanavir SmPC gives separate advice. It does not recommend atorvastatin, and if atorvastatin is strictly necessary, it advises the lowest possible dose with close safety monitoring. Use pravastatin and fluvastatin with caution (atazanavir SmPC, EMA). Explain to the patient the risk of myopathy and its signs: unexplained muscle pain, tenderness or weakness, especially with malaise or fever (lovastatin FDA label). If muscle pain, weakness or cramps appear, measure creatine kinase (CK). Stop lovastatin if CK is above 5 times the upper limit of normal without strenuous exercise or if myopathy is suspected. With severe muscle symptoms, consider stopping it even at a lower CK (lovastatin SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Atazanavir

Other interactions with Lovastatin